Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Clinical trial NCT00621361 · COMPLETED
Trial details
- NCT number
- NCT00621361
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2008-02-01
- Primary completion
- 2009-08-01
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.